Pharmaxis Announces First Patient Enrolled in Clinical Trial for New Cancer Treatment
Release Date: 22/02/2021 9:50am
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced it has enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis.
The phase 1c/2a trial cleared by the FDA under the Investigational New Drug (IND) scheme aims to demonstrate that PXS-5505, the lead asset in Pharmaxis’ drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Pharmaxis has completed site initiation at several Australian and South Korean hospitals and the first patient has been enrolled. The dose escalation phase of the study that aims to select the optimum dose of PXS-5505. This first phase, that will recruit up to 18 patients, is expected to conclude and report in 2H 2021 and will be followed by a six-month dose expansion phase (24 patients) to evaluate safety and efficacy. Sites in other countries including the USA will be added for the dose expansion phase.
Categories: News and Media